VIDEO: Obinutuzumab useful for refractory thrombotic thrombocytopenic purpura
Click Here to Manage Email Alerts
In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the use of obinutuzumab in patients with thrombotic thrombocytopenic purpura.
Sosa, an associate professor and chief of the division of hematology at Fox Chase Cancer Center, highlighted the study, which studied the use of obinutuzumab (Gazyva, Genentech) in patients who were either refractory or had an intolerance to rituximab.
“What we are seeing is that this is a really good option for obinutuzumab to be used in those patients that are refractory to rituximab, or perhaps intolerant to the medication, because this is a very challenging disease and relapses are frequent,” Sosa said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts